Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics reported a net loss of $(1.81) million for the six months ended June 30, 2026, a significant increase from $(20,860) in the prior year, and issued a going concern warning. Despite the financial challenges, the company saw an increase in service revenue to $250,000 and made progress on strategic initiatives, including a Nasdaq uplisting application and a partnership with TechForce Robotics. Its joint venture, GMP Bio, is also advancing OT-101 towards Phase 2 and 3 trials.

Oncotelic Therapeutics, Inc. presented a corporate presentation to its employees, directors, officers, and advisors on July 13, 2026. This presentation, which provides an overview of the company, is included as Exhibit 99.1 to the Current Report on Form 8-K. The information is furnished for informational purposes and is not considered "filed" under specific sections of the Securities Exchange Act of 1934.

Oncotelic Therapeutics, Inc. approved the grant of 17,796 Restricted Stock Units (RSUs) to its directors, officers, employees, and advisors. Each RSU represents the right to receive one share of Series A Convertible Preferred Stock, convertible into 1,000 shares of Common Stock. Vesting is conditional upon the company's common stock uplisting to a national stock exchange by June 30, 2027, and the recipient's continued service for six months post-uplisting.

Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Pacific Pier Capital II, LP, securing $178,410 in gross principal via a convertible promissory note. The note carries a 12% interest rate and a 12% original issue discount, maturing in one year. As part of the financing, the company also issued 500,000 commitment shares. The note is convertible into common stock at a fixed price of $0.06 per share or 85% of the lowest traded price, subject to a 4.99% beneficial ownership limitation.

Oncotelic Therapeutics reported a net loss of $(2.19) million for the first quarter of 2026, significantly wider than the $(0.29) million loss in Q1 2025. The company also disclosed a negative working capital of approximately $(16.3) million and negative cash flows from operations, raising substantial doubt about its ability to continue as a going concern. Despite financial challenges, Oncotelic entered a strategic partnership with TechForce Robotics to commercialize an AI-enabled, GMP-compliant robotics platform and continues development of its immuno-oncology therapeutics through its GMP Bio joint venture.

Oncotelic Therapeutics' wholly owned subsidiary, Oncotelic Inc., completed a triangular merger on May 1, 2026, involving Neurobridge IP Holdings Incorporated and Lunai Bioworks, Inc. As part of the transaction, Oncotelic Inc. contributed its intellectual property assets to Neurobridge IP Holdings. In consideration for the merger, Lunai Bioworks issued 8 shares of Series B Convertible Preferred Stock with an aggregate stated value of $20,000,000, of which Oncotelic received 5 shares valued at $12,500,000. Oncotelic also secured a perpetual, royalty-free, exclusive license to use the assigned IP in all fields except Biodefense and Alzheimer's Disease.

Oncotelic Therapeutics, Inc. announced its financial results for the fiscal year ended December 31, 2025, reporting a significant net income after tax of approximately $249.0 million. This marks a substantial improvement from a net loss of approximately $4.8 million in the prior fiscal year. The positive financial performance was primarily attributed to a non-cash increase in the estimated fair value of the company's investment in its joint venture, GMP Biotechnology Limited.

Oncotelic Therapeutics, Inc. has filed its annual report on Form 10-K for the fiscal year ended December 31, 2025. The company confirmed it has filed all reports required by the Securities Exchange Act of 1934 during the preceding 12 months. Oncotelic Therapeutics is designated as a non-accelerated filer and a smaller reporting company.